Sanofi's acquisition of INBRX-101 is a strategic move to bol...
Sanofi's acquisition of INBRX-101 is a strategic move to bolster its portfolio in rare diseases and immune-mediated respiratory conditions, aligning with its transition into a pure-play biopharmaceutical company.
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3213Followers
0Following
7980Visitors
Follow